Journal
FUTURE ONCOLOGY
Volume 8, Issue 6, Pages 687-695Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.12.54
Keywords
antibody; bispecific; CD19; CD30; diabody; Hodgkin's lymphoma; non-Hodgkin's lymphoma; TandAb (R)
Categories
Ask authors/readers for more resources
Tandem diabodies (TandAbs (R)) are tetravalent bispecific molecules comprised of antibody variable domains with two binding sites for each antigen. RECRUIT-TandAbs can simultaneously engage an immune system effector cell, such as a natural killer cell or a cytotoxic T cell, and an antigen expressed specifically on a cancer cell, thus leading to killing of the cancer cell. Recruitment of immune effector cells is highly specific and mediated via binding of the TandAb to molecules expressed on the surface of these cells. Furthermore, the absence of an Fc domain allows TandAbs to avoid certain IgG-mediated side effects. With a molecular weight of approximately 110 kDa, TandAbs are far above the first-pass renal clearance limit, offering a pharmacokinetic advantage compared with smaller bispecific antibody formats. This article reviews the RECRUIT-TandAb technology and the therapeutic potential of these molecules.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available